- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06318884
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
A Phase Ia/Ib Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SCTB35 in Patients With CD20+ Relapse/Refractory B-cell Non-Hodgkin Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Junfan Ma, Ph.D
- Phone Number: 86-010-58628288
- Email: junfan_ma@sinocelltech.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Beijing Cancer Hospital
-
Contact:
- Yuqin Song, M.D.
- Phone Number: 010-88196118
- Email: SongYQ_VIP@163.com
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Cancer Hospital
-
Contact:
- Keshu Zhou, M.D.
- Phone Number: 13674902391
- Email: dr_zkshu23810@163.com
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Tianjin Medical University Cancer Institute & Hospital
-
Contact:
- Lanfang Li, M.D.
- Phone Number: 18622221613
- Email: lilanfangmeng@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients are eligible to be included in the study only if all the following conditions are met:
- Age ≥ 18 years
Histologically or cytologically confirmed CD20+ mature B-cell neoplasm
For dose-escalation phase:
- De novo or transformed diffuse large B-cell lymphoma (DLBCL)
- High-grade B-cell lymphoma (HGBCL)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- Follicular lymphoma (FL)
- Mantle cell lymphoma
- Small lymphocytic lymphoma (SLL)
- Marginal zone lymphoma (MZL) (nodal, extranodal or mucosa associated)
For dose expansion phase:
- FL cohort: histologic confirmed FL grade 1, 2, or 3a at initial diagnosis without clinical or pathological evidence of transformation
- LBCL cohort: including histologic confirmed DLBCL, not otherwise specified (NOS), Epstein-Barr virus+ DLBCL, transformed DLBCL from indolent subtypes, HGBCL, NOS, double/triple-hit HGBCL, FL grade 3b, and PMBCL
For dose-escalation phase:
Relapsed, progressive and/or refractory disease after adequate systemic therapy containing at least an anti-CD20 monoclonal antibody (e.g. rituximab)
- Patients must have exhausted or are ineligible for all standard therapeutic options
- Patients with indolent lymphoma (FL, MZL or SLL) must have a need for treatment initiation based on symptoms and/or disease burden
For dose-expansion phase:
Relapsed, progressive and/or refractory disease following ≥ 2 prior lines of adequate systemic therapy containing at least an anti-CD20 monoclonal antibody (e.g. rituximab)
- At least 1 measurable site of disease based on computed tomography (CT) or magnetic resonance imaging (MRI) (defined as a clearly nodal lesion with the long axis > 1.5 cm or extranodal lesion with the long axis > 1.0 cm). Lesions that have previously received radiotherapy can be considered measurable only after confirming the presence of progression or residual lesions. (for the dose-escalation phase: a evaluable site of disease is allowed).
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
Adequate hepatic/hematologic/renal/cardiac functions indicated by laboratory values
- Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L within 7 days before first dose of study drug (without growth factor support). There is an exception for patients with bone marrow involvement in which case ANC must be ≥ 0.75 x 10^9/L
- Platelets > 75 x 10^9/L within 7 days before first dose of study drug (without growth factor support or transfusion). There is an exception for patients with bone marrow involvement in which case platelets must be ≥ 50 x 10^9/L
- Hemoglobin > 90 g/L within 7 days before first dose of study drug (independent of growth factor support or transfusion).
- Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or creatinine clearance ≥ 45 mL/min as estimated by Cockcroft-Gault equation
- Adequate liver function indicated by: i) Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase ≤ 3 x ULN; ii) Alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase ≤ 3 x ULN; iii) Total bilirubin level ≤ 1.5 x ULN (unless documented Gilbert's syndrome).
- Left ventricular ejection fraction ≥ 50%;
- Expected survival time is more than 3 months
Exclusion Criteria:
A patient who conforms to any of the following criteria should be excluded from the study:
- Any prior therapy with an bispecific antibody of the same class
- Eligible for high dose chemotherapy with hematopoietic stem cell transplantation (HSCT)
- Known central nervous system (CNS) involvement by lymphoma
Known past or current malignancy other than inclusion diagnosis, with the following exceptions:
- Cervical carcinoma of Stage Ib or less
- Non-invasive basal cell or squamous cell skin carcinoma
- Non-invasive, superficial bladder cancer
- Prostate cancer with a current prostate-specific antigen (PSA) level <0.1 ng/mL
- Any curable cancer with a complete response (CR) of >2 years duration
Known clinically significant cardiac disease, including:
- Onset of unstable angina pectoris or acute myocardial infarction within 6 months prior to signing Informed Consent Form (ICF)
- Congestive heart failure prior to signing ICF (meets the criteria of New York Heart Association Classification III or IV)
- Clinically significant arrhythmia prior to signing ICF
- History of interstitial lung disease or uncontrolled lung diseases, or evidence of dyspnea at rest or pulse oximetry < 93% while breathing room air.
Confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy (including >20mg/day prednisolone [or equivalent], but low-dose prednisolone is allowed). The well controlled autoimmune disease can be enrolled at investigator's discretion, including:
- Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone
- Patients with a history of type 1 diabetes mellitus who were well controlled (defined as a screening hemoglobin A1c < 8% and no urinary ketoacidosis)
- Patients with skin disease who were not treated with systemic corticosteroid
- History of seizure disorder or confirmed progressive multifocal leukoencephalopathy (PML)
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
- Known any major episode of active infection requiring treatment with systemic antibiotics within 2 weeks prior to signing ICF
- Positive for human immunodeficiency virus (HIV) antibody. Positive for hepatitis B antibody (except for only the positive HBsAb) with detectable hepatitis B virus (HBV) DNA. Positive for hepatitis C antibody with detectable hepatitis C virus (HCV) RNA
- Chimeric antigen receptor T-cell (CAR-T) therapy within 100 days prior to first SCTB35 administration (only applicable for dose-expansion phase)
- Autologous HSCT within 100 days prior to first SCTB35 administration, or any prior allogeneic HSCT or solid organ transplantation
- Received major surgery within 4 weeks prior to first SCTB35 administration, or planned to receive major surgery during the study
- Received any chemotherapeutic agent, other anti-cancer agent, or investigational drug (monoclonal antibody, radioimmunoconjugate, antibody-drug conjugate or otherwise) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to first SCTB35 administration
- Exposed to live or live attenuated vaccine within 4 weeks prior to first SCTB35 administration, or planned to receive these vaccines during the study
- Pregnancy or breast feeding. During the study and for 6 months after last administration of SCTB35, a woman of childbearing potential or a man who is sexually active with a woman of childbearing potential disagrees to practice a highly effective method of birth control.
- Patient has any condition for that, in the opinion of the investigator, participation could prevent, limit, or confound the protocol-specified assessments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SCTB35
SCTB35 injection is subcutaneously given every week for the first 4 cycles, and thereafter every 3 weeks.
Cycles will be repeated every 3 weeks until disease progression, study discontinuation, or death, whichever occurs first.
|
SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts.
Then, the RP2D and another appropriate dose of SCTB35 will be applied for the dose-expansion cohorts.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-escalation part: incidence rate of adverse event (AE)
Time Frame: From first dose until 28 days after last dose of study drug or until study completion or participant withdrawal (up to 3 years)
|
To evaluate the incidence rates of treatment emergent adverse event (TEAE), treatment-related TEAE (TRAE), serious adverse event (SAE), adverse event with special interest (AESI)
|
From first dose until 28 days after last dose of study drug or until study completion or participant withdrawal (up to 3 years)
|
Dose-expansion part: objective response rate (ORR)
Time Frame: From first dose until up to 2 years
|
ORR is defined as the percentage of patients achieving complete response (CR) or partial response (PR) as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Dose-escalation part: dose limited toxicity (DLT)
Time Frame: During the first cycle (21 days)
|
To determine the maximum tolerated dose (MTD) and/or RP2D to be studied in the dose-expansion part
|
During the first cycle (21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-escalation part: ORR
Time Frame: From first dose until up to 2 years
|
ORR is defined as the percentage of patients achieving CR or PR as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Dose-escalation part: CR rate (CRR)
Time Frame: From first dose until up to 2 years
|
CR rate is defined as the percentage of patients with CR as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Dose-escalation part: duration of response (DOR)
Time Frame: From first dose until up to 2 years
|
DOR is defined as the time from first documented objective response to PD or death due to any cause, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Dose-escalation part: progression-free survival (PFS)
Time Frame: From first dose until up to 2 years
|
PFS is defined as the time from first dose to first documented PD or death due to any cause, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Dose-escalation part: time to response (TTR)
Time Frame: From first dose until up to 2 years
|
TTR is defined as the time from first dose to first documented objective response observed for patients who achieved a CR or PR, as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Dose-escalation part: overall survival (OS)
Time Frame: From first dose until up to 5 years
|
OS is defined as the time from first dose to death due to any cause
|
From first dose until up to 5 years
|
Dose-escalation part: blood concentrations of SCTB35
Time Frame: From first dose until up to 2 years
|
The pharmacokinetics of SCTB35 will be analyzed based on the drug concentrations at respective timepoints in the blood samples (or blood derivative)
|
From first dose until up to 2 years
|
Dose-escalation part: anti-drug antibodies of SCTB35
Time Frame: From first dose until up to 2 years
|
Blood samples (or blood derivative) will be screened for antibodies binding to SCTB35
|
From first dose until up to 2 years
|
Dose-expansion part: CRR
Time Frame: From first dose until up to 2 years
|
CR rate is defined as the percentage of patients with CR as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Dose-expansion part: DOR
Time Frame: From first dose until up to 2 years
|
DOR is defined as the time from first documented objective response to PD or death due to any cause, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Dose-expansion part: PFS
Time Frame: From first dose until up to 2 years
|
PFS is defined as the time from first dose to first documented PD or death due to any cause, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Dose-expansion part: TTR
Time Frame: From first dose until up to 2 years
|
TTR is defined as the time from first dose to first documented objective response observed for patients who achieved a CR or PR, as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Dose-expansion part: OS
Time Frame: From first dose until up to 5 years
|
OS is defined as the time from first dose to death due to any cause
|
From first dose until up to 5 years
|
Dose-expansion part: AE
Time Frame: From first dose until up to 2 years
|
To evaluate the incidence rates of TEAE, TRAE, SAE, AESI
|
From first dose until up to 2 years
|
Dose-expansion part: blood concentrations of SCTB35
Time Frame: From first dose until up to 2 years
|
The pharmacokinetics of SCTB35 will be analyzed based on the drug concentrations at respective timepoints in the blood samples (or blood derivative)
|
From first dose until up to 2 years
|
Dose-expansion part: anti-drug antibodies of SCTB35
Time Frame: From first dose until up to 2 years
|
Blood samples (or blood derivative) will be screened for antibodies binding to SCTB35
|
From first dose until up to 2 years
|
Dose-escalation part: best of overall response (BOR)
Time Frame: From first dose until up to 2 years
|
BOR is defined as the percentage of patients achieving best response from the first dose to first documented disease progression (PD) or new anticancer therapy, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Dose-expansion part: BOR
Time Frame: From first dose until up to 2 years
|
BOR is defined as the percentage of patients achieving best response from the first dose to first documented PD or new anticancer therapy, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014
|
From first dose until up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yuqin Song, M.D., Peking University Cancer Hospital & Institute
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCTB35-X101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin Lymphoma, B-cell
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
University of NebraskaBristol-Myers SquibbRecruitingFollicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
AstraZenecaRecruitingFollicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin LymphomaKorea, Republic of, United States, Japan, Australia, Taiwan
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
Affimed GmbHTerminatedRefractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin LymphomaUnited States, Czechia, Germany, Poland
Clinical Trials on SCTB35 injection
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated
-
Royan InstituteCompletedMyocardial InfarctionIran, Islamic Republic of
-
National Taiwan University HospitalCompleted